Unmet Treatment Needs Propelling Growth of Asia Pacific ARDS Treatment Market

Triveni Triveni
Published on Apr 20, 2023

The Acute Respiratory Distress Syndrome (ARDS) Treatment Market is projected to achieve a strong revenue CAGR during the forecast period, primarily driven by the increasing incidence of chronic respiratory diseases, including COVID-19. ARDS is a potentially life-threatening lung injury that causes the accumulation of fluid in the lungs' tiny air sacs called alveoli. Most individuals who develop ARDS are already hospitalized for an illness or trauma, such as COVID-19. The accumulation of fluids in the lungs' alveoli reduces the amount of oxygen entering the bloodstream, resulting in organs being deprived of adequate oxygen to function properly. ARDS usually develops within hours to days after the onset of injury or infection in people with various illnesses. The severity of the condition affects the individual's survival chances, with older individuals having lower chances of survival. ARDS is commonly caused by severe pneumonia, toxic substance inhalation, sepsis, head or chest injuries, COVID-19, and other serious illnesses that damage the lungs' membrane sacs.

The ARDS market is poised for growth globally due to factors such as aging population, increasing healthcare expenditure, and strategic initiatives by key players. The market has witnessed significant investments in research and development from public and private entities, leading to the development of novel therapies. North America is expected to dominate the market, driven by extensive research activities, advanced technology adoption, rising prevalence of chronic respiratory disorders, accurate diagnosis, and management recommendations for ARDS patients. Meanwhile, the Asia Pacific region is anticipated to witness the fastest growth owing to the increasing incidence of ARDS and the growing number of intensive care units. Although the ARDS treatment market in this region is still in its nascent stage, the demand for effective treatment options is expected to drive market expansion. Additionally, Japan is expected to play a key role in the growth of the Asia Pacific ARDS market, given its focus on biotechnology research and development.

Request a sample Report of ARDS Treatment Market @

Major companies in ARDS Treatment Market:

  • Johnson and Johnson Services, Inc.
  • Daiichi Sankyo Company Ltd.
  • Sanofi
  • Pfizer Inc.
  • Novartis AG
  • Gilead Sciences, Inc.
  • Mylan NV
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • GlaxoSmithKline, Plc.

Request latest Report Insights of  ARDS Treatment Market @

Driving Factors in ARDS Treatment Market:

  1. Increasing prevalence of COVID-19 and other chronic respiratory diseases leading to higher demand for ARDS treatments.
  2. Growing ageing population worldwide, resulting in higher incidence of ARDS and related disorders.
  3. Rising healthcare costs and government initiatives to promote affordable and effective treatments for ARDS.
  4. Advancements in technology and research and development activities by market participants leading to more effective and innovative treatments.
  5. Emergence of management recommendations for patients with ARDS, resulting in better diagnosis and treatment outcomes.

Restraints in ARDS Treatment Market:

  1. High cost of treatment
  2. Lack of awareness and understanding of the disease
  3. Stringent regulatory framework and approval process for new treatments
  4. Limited availability of advanced treatment facilities in underdeveloped regions
  5. Risk associated with the use of ventilators in severe cases of ARDS
  6. Limited number of approved treatment options
  7. Adverse effects associated with ARDS treatments
  8. Limited reimbursement options for patients
  9. Ethical concerns related to clinical trials
  10. Economic slowdown due to COVID-19 pandemic

Request a Report Customization of ARDS Treatment Market @

Notable Innovations in ARDS Treatment Market:

  1. Extracorporeal Membrane Oxygenation (ECMO) Therapy: ECMO is a technique that provides prolonged cardiac and respiratory support by circulating the patient's blood through an oxygenator and carbon dioxide remover outside of the body. It has been used successfully in patients with ARDS.
  2. Stem Cell Therapy: Stem cell therapy is a promising treatment option for ARDS. It involves the injection of stem cells into the lungs to promote healing and reduce inflammation.
  3. Gene Therapy: Gene therapy is a technique that involves the transfer of genetic material into a patient's cells to treat or prevent disease. It is being studied as a potential treatment for ARDS.
  4. Novel Drug Therapies: Several novel drug therapies are being developed to treat ARDS. These drugs target specific molecular pathways involved in the development of ARDS.
  5. Mechanical Ventilation Strategies: Mechanical ventilation strategies, such as high-frequency oscillatory ventilation (HFOV) and prone positioning, are being studied as potential treatments for ARDS. These techniques aim to improve oxygenation and reduce the risk of ventilator-induced lung injury.

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, TouchPoints, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provide our clients with the ability to secure an edge over their respective competitors.

Contact Us:

John W
Head of Business Development
Reports And Data | Web:
Direct Line: +1-212-710-1370
LinkedIn | Twitter | Blogs